The Committee for Medicinal Products for Human Use (CHMP) is the European Medicines Agency's (EMA) committee responsible for preparing the Agency's opinions on all human medicine issues.
The March 2026 plenary meeting occurred from 23 to 26 March 2026 at EMA headquarters in Amsterdam, Netherlands. It endorsed EU recommendations for the seasonal influenza vaccine composition for the 2026/2027 season, aligning with WHO observations on circulating virus strains. Quadrivalent vaccines were noted for regions still transitioning from including B/Yamagata lineage.
Other outcomes included positive opinions for marketing authorisations of new medicines such as Adstiladrin, Imdylltra, Joenja, Zeppelca, and Bopediat, extensions for 13 existing medicines, and various scientific guidelines and referrals.
